Know the Facts about Coronavirus Disease 2019 (COVID-19)

Condition | Cancer

BIG 16 05 AFT 27

  • IRB Number: BIG 16-05/AFT-27
  • Contact Name: Blair Thomas, RN BSN
  • Status: Enrolling
  • Phone: (585) 747-4555
  • Lead Researcher: Peter Bushunow, MD


A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti-PD-L1) Antibody in Combination with Adjuvant Anthracycline/Taxane-Based Chemotherapy versus Chemotherapy Alone in Patients with Operable Trip-Negative Breast Cancer